VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Operating Income : $-7.05 Mil (TTM As of Jun. 2008)

View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals Operating Income?

VioQuest Pharmaceuticals's Operating Income for the three months ended in Jun. 2008 was $-1.03 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2008 was $-7.05 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. VioQuest Pharmaceuticals's Operating Income for the three months ended in Jun. 2008 was $-1.03 Mil. VioQuest Pharmaceuticals's Revenue for the three months ended in Jun. 2008 was $0.00 Mil. Therefore, VioQuest Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2008 was %.

VioQuest Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. VioQuest Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2008 was -8,939.13%. VioQuest Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2008 was -13,264.52%.

VioQuest Pharmaceuticals Operating Income Historical Data

The historical data trend for VioQuest Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals Operating Income Chart

VioQuest Pharmaceuticals Annual Data

Trend

Dec98

Dec99

Dec00

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Operating Income

Get a 7-Day Free Trial

-2.03

-4.06

-10.40

-5.28

-8.78

VioQuest Pharmaceuticals Quarterly Data
	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08
Operating Income	Get a 7-Day Free Trial															-2.14	-2.67	-1.68	-1.67	-1.03

VioQuest Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.05 Mil.

VioQuest Pharmaceuticals (OTCPK:VOQP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

VioQuest Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2008 is calculated as:

	ROC % (Q: Jun. 2008 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2008 )	+	Invested Capital (Q: Jun. 2008 ))	/ count )
=	-4.112 * ( 1 - 0% )	/	( (0.047	+	0.045)	/ 2 )
=	-4.112	/	0.046
=	-8,939.13 %

where

	Invested Capital		(Q: Mar. 2008 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.698	-	3.452	-	( 0.306	-	max(0, 3.452	-	0.651	+	0.306	))
=	0.047

	Invested Capital		(Q: Jun. 2008 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.177	-	2.694	-	( 0.814	-	max(0, 2.694	-	1.132	+	0.814	))
=	0.045

Note: The Operating Income data used here is four times the quarterly (Jun. 2008) data.

2. Joel Greenblatt's definition of Return on Capital:

VioQuest Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2008 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2008 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2008		Q: Jun. 2008
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.112	/	( ( (0.032 + max(-3.107, 0))	+	(0.03 + max(-2.376, 0)) )	/	2 )
=	-4.112	/	( ( 0.032	+	0.03 )	/	2 )
=	-4.112	/	0.031
=	-13,264.52 %

where Working Capital is:

	Working Capital		(Q: Mar. 2008 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.345)	-	(3.452	+	0	+	0)
=	-3.107

	Working Capital		(Q: Jun. 2008 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.318)	-	(2.694	+	0	+	0)
=	-2.376

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2008) EBIT data.

3. Operating Income is also linked to Operating Margin %:

VioQuest Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2008 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2008 )	/	Revenue (Q: Jun. 2008 )
	=	-1.028	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

VioQuest Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 2287, Minneapolis, MN, USA, 55402

Website

VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.

Executives

Mark D Dacko	director, officer: CFO and Secretary	800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker	officer: V.P. & Chief Financial Officer	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz	officer: CFO and Treasurer	65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam	director
Michael Weiser	director	C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli	director, officer: Secretary	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf	director, officer: President and CEO	C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz	10 percent owner	WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen	director	TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines